sintilimab + chidamide

Sintilimab + chidamide is an investigational combination therapy comprising the anti-PD-1 monoclonal antibody sintilimab and the oral histone deacetylase (HDAC) inhibitor chidamide. This regimen is being evaluated primarily for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Sintilimab functions as an immune checkpoint inhibitor by blocking the interaction between the PD-1 receptor on T cells and its ligands (PD-L1/PD-L2), thereby restoring anti-tumor immune responses. Chidamide, a benzamide-class HDAC inhibitor, selectively inhibits HDAC1, 2, 3, and 10, leading to epigenetic modulation that can enhance the immunogenicity of tumor cells and potentially synergize with PD-1 blockade. The combination is currently being studied in Phase II clinical trials led by Fudan University (NCT04512534) to assess its efficacy and safety in patients who have failed prior therapies.

Other names

Sintilimab plus ChidamideSintilimab and ChidamideTucidinostat